The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer
Open accessPublished version of a preprint
Abstract
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharmacologic restoration of p16INK4A function with inhibitors of CDK4 and CDK6 (CDK4/6) has shown limited clinical efficacy in PDAC. Here, we found that concurrent treatment with both a CDK4/6 inhibitor (CDK4/6i) and an ERK–MAPK inhibitor (ERKi) synergistically suppresses the growth of PDAC cell lines and organoids by cooperatively blocking CDK4/6i-induced compensatory upregulation of ERK, PI3K, antiapoptotic signaling, and MYC expression. On the basis of these findings, a Phase I clinical trial was initiated to evaluate the ERKi ulixertinib in combination with the CDK4/6i palbociclib in patients with advanced PDAC (NCT03454035). As inhibition of other proteins might also counter CDK4/6i-mediated signaling changes to increase cellular CDK4/6i sensitivity, a CRISPR-Cas9 loss-of-function screen was conducted that revealed a spectrum of functionally diverse genes whose loss enhanced CDK4/6i growth inhibitory activity. These genes were enriched around diverse signaling nodes, including cell-cycle regulatory proteins centered on CDK2 activation, PI3K–AKT–mTOR signaling, SRC family kinases, HDAC proteins, autophagy-activating pathways, chromosome regulation and maintenance, and DNA damage and repair pathways. Novel therapeutic combinations were validated using siRNA and small-molecule inhibitor–based approaches. In addition, genes whose loss imparts a survival advantage were identified (e.g., RB1, PTEN, FBXW7), suggesting possible resistance mechanisms to CDK4/6 inhibition. In summary, this study has identified novel combinations with CDK4/6i that may have clinical benefit to patients with PDAC. Significance: CRISPR-Cas9 screening and protein activity mapping reveal combinations that increase potency of CDK4/6 inhibitors and overcome drug-induced compensations in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Co-targeting KRAS and CDK4/6 showed synergism in KRAS-mutant PDAC preclinical models [126].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [126]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A therapeutic approach targeting CDKN2A in KRAS-mutated PDAC is under investigation; however, clinical activity of CDK4/6 inhibitors was not seen in early-phase trials55,56.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [55]
In the citing paper
“A therapeutic approach targeting CDKN2A in KRAS-mutated PDAC is under investigation; however, clinical activity of CDK4/6 inhibitors was not seen in early-phase trials55,56.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., & Zhang, B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz401 · Cited by 3,144
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
McGuigan, A., Kelly, P., Turkington, R. C., Jones, C., Coleman, H. G., & McCain, R. S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4846 · Cited by 1,908
Oughtred, R., Rust, J., Chang, C., Breitkreutz, B., Stark, C., Willems, A., Boucher, L., Leung, G., Kolas, N., Zhang, F., et al. (2021) · Protein Science · doi:10.1002/pro.3978 · Cited by 1,858
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
Cited by
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Self-citationA Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 192
Bai, X., Guo, Y.-R., Zhao, Z., Li, X., Dai, D.-Q., Zhang, J., Li, Y.-S., & Zhang, C. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217772 · Cited by 158
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 114
Metadata
- Authors
- Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., Ozkan-Dagliyan, I., Baldelli, E., Calvert, V., Pierobon, M., Sorrentino, J. A., Beelen, A. P., Bublitz, N., Lüthen, M., Wood, K. C., Petricoin, E. F., Sers, C., McRee, A. J., Cox, A. D., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- 3Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- George Mason University (US)
- 8G1 Therapeutics, Research Triangle Park, North Carolina.
- German Cancer Research Center (DE)
- Duke University (US)
- Corresponding author
- Der, Channing J.
- ORCID
- Goodwin, Craig M.
- Waters, Andrew M.
- Klomp, Jennifer E.
- Javaid, Sehrish
- Bryant, Kirsten L.
- Stalnecker, Clint A.
- Drizyte-Miller, Kristina
- Papke, Bjoern
- Yang, Runying
- Amparo, Amber M.
- Ozkan-Dagliyan, Irem
- Baldelli, Elisa
- Calvert, Valerie
- Pierobon, Mariaelena
- Sorrentino, Jessica A.
- Beelen, Andrew P.
- Bublitz, Natalie
- Lüthen, Mareen
- Wood, Kris C.
- Petricoin, Emanuel F.
- Sers, Christine
- McRee, Autumn J.
- Cox, Adrienne D.
- Der, Channing J.
- Venue
- Cancer Research
- Published
- 2022-11-08
- Volume
- 83
- Issue
- 1
- Pages
- 141-157
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC9812941
- OpenAlex
- W4308510057
- Cited by
- 168
- References
- 60
- Citations by year
- 2026: 32 · 2025: 62 · 2024: 43 · 2023: 31
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Cancer Institute (T32CA009156, F32CA221005, F32CA239328, P50CA196510, R37CA251877, F32CA232529, R01CA42978, R01CA175747, R01CA223775, U01CA199235, P01CA203657, R35CA232113)
- American Cancer Society (PF-18-061, PF-20-069, PF-22-066-01)
- Royster Society of Fellows
- Pancreatic Cancer Action Network (15-70-25-BRYA, 15-90-25-DER)
- Sky Foundation
- Deutsche Forschungsgemeinschaft (DFG PA 3051/1-1)
- Slomo and Cindy Silvian Foundation
- National Institutes of Health (CA203657)
- U.S. Department of Defense (W81XWH-15-1-0611)
- Lustgarten Foundation (388222)
- Julie M. Brown and Christina Gianoplus Colon Cancer Foundation
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6 inhibitors, p16INK4a, CDKN2A loss, ulixertinib, palbociclib, combination therapy, compensatory signaling, PI3K/AKT/mTOR pathway, c-Myc, CRISPR-Cas9 loss-of-function screen, drug resistance, RB1, PTEN, FBXW7, Src family kinases, histone deacetylase, autophagy, DNA damage and repair, cell cycle regulation
- MeSH terms
- Humans, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Phosphatidylinositol 3-Kinases, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-22-0391
- The paper
- Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., Ozkan-Dagliyan, I., Baldelli, E., Calvert, V., Pierobon, M., Sorrentino, J. A., Beelen, A. P., Bublitz, N., Lüthen, M., Wood, K. C., . . . Der, C. J. (2023). Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-22-0391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.